Rocio Martin Hoyos

Rocio Martin Hoyos , M.S., M.B.A., joined Kronos Bio in January 2021 as Vice President, Commercial Strategy. Prior to joining Kronos Bio, Rocio served as VP Global and US Marketing at Audentes Therapeutics, where she established the marketing function and led the global strategy and launch readiness for AT132, a gene therapy in development for X-Linked myotubular myopathy. Until early 2019, she worked at Ultragenyx as Global Commercial Lead across multiple therapies for rare diseases (MEPSEVII®, DOJOLVI®, DTX301 and DTX401). Prior to working in rare diseases, Rocio spent eight years working in hematology/oncology at Celgene where she held roles of increasing responsibility at the EMEA and global levels for pipeline therapies and commercial products across multiple indications and disease areas. Rocio began her career as an investment analyst at Ysios Capital Partners. She holds an M.S. in biochemistry from Universidad Autonoma de Madrid and an M.B.A. from IESE Business School in Barcelona.